fda remove semaglutide from shortage list As of February 21, 2025, the updated its drug list, marking the injection shortage as resolved. Semaglutide injections are no longer classified as “currently in shortage,” and both 503A GLP-1 Drugs: FDA Removes Semaglutide

The complete GLP-1 purchasing guide covers vendor evaluation across the full compound class, including considerations specific to each peptide

Every batch of IGF-1 LR3 Peptide ships with a verified certificate of analysis (COA) , confirming identity, purity, and sterility because transparency is non-negotiable when sourcing research peptides free shipping USA

C

New peptides emerging Research continues developing new peptides with improved characteristics

A poster from osteoarthritis experts looking at health economic modelling suggests that, in certain situations over a five year horizon, a GLP-1 agonist intervention could make pharmacoeconomic sense in knee osteoarthritis (abstract 1050)